

## Objectives

- Insulin is a life-saving pharmacological therapy used in the management of blood glucose for many diabetic patients. However, insulin has been identified as a high alert medication<sup>1</sup> as it has the potential to cause detrimental patient harm when used in error; particularly an excessive dose can lead to life-threatening hypoglycemia.
- Medication incident reporting can be used to enhance understanding of factors that may contribute to insulin-related medication incidents.
- The objective of this multi-incident analysis was to examine insulin-related medication incidents and determine potential system-based improvements that may be customized in pharmacy practice to enhance medication safety.

## Methodology

- Reports of medication incidents involving insulin were extracted from the Institute for Safe Medication Practices Canada (ISMP Canada) Community Pharmacy Incident Reporting (CPhIR) Program<sup>2</sup> between January and December 2014.
- CPhIR provides users with a secure online interface to document medication incidents, export data for analysis, and view comparisons of individual pharmacy and aggregate data. CPhIR program depends on voluntary reporting of medication incidents.
- After a review of 226 incidents, 81 were included in this qualitative, multi-incident analysis. The incidents were then analyzed and categorized into main themes and subthemes.

## Results

- The four main themes identified were presented in [Table 1](#).
- Sample cases, potential contributing factors, and potential system-based solutions are provided in [Tables 2, 3, 4, and 5](#). Incident examples provided were limited to what was inputted by pharmacy practitioners to the “Incident Description” field of the CPhIR program.

**Table 1.**

Main Themes and Subthemes

### Product Selection

Subthemes:  
Prescribing  
Order Entry  
Dispensing

### Therapeutic Regimen Change

### Dosage Calculations

### Storage Requirements

**Table 2.**

Theme 1 – Product Selection (related to unique insulin properties)

The patient noticed his insulin box was different than [what] he had before. He should have received Novolin® ge NPH and had been given Novolin® ge 30/70 in error.

**Potential contributing factors:**

- Variety of dosage forms (i.e. rapid-acting, short-acting, long-acting, premixed, vials, cartridges, preloaded pens) available
- Look-alike, sound-alike names and packaging
- Proximity of storage of look-alike, sound-alike insulin products
- Lack of independent double checks
- Environmental distractions
- Confirmation bias

**Potential system-based solutions:**

- Consider programming pharmacy software to include both generic and brand names for insulin at pharmacy order entry and incorporate warning flags in pharmacy software to alert for potential mix-up.<sup>3,4</sup>
- Perform independent double checks throughout the entire pharmacy workflow. When a patient picks up his/her insulin, include a physical review (i.e. packages, labels, insulin product) as they are provided to the patient.<sup>3,5,6</sup>
- Segregate insulin products by storing them according to their onset of action in well-differentiated areas of the refrigerator.<sup>3,6,7</sup>

**Table 3.**

Theme 2 – Therapeutic Regimen Change

Prescription had specific instructions for use and was copied over by an old one with just “use as directed” on it.

**Potential contributing factors:**

- Frequent dose changes
- Copying previous prescriptions

**Potential system-based solutions:**

- Consider programming the pharmacy software or developing policies to restrict the process of copying from previous prescriptions for all insulin prescriptions.<sup>3</sup>
- Perform independent double checks throughout the entire pharmacy workflow. Encourage patients to actively participate in conversation when providing medication counselling.<sup>3,5,8</sup>
- Consider performing a comprehensive diabetes-focused medication review when a patient has a significant change in insulin usage.

**Table 4.**

Theme 3 – Dosage Calculations

Prescription for 4-10 units of insulin a day x 90 days [was] entered as 45 mLs. Only 15 mLs were required.

**Potential contributing factors:**

- Knowledge deficit on how to calculate insulin units to millilitres and days supply

**Potential system-based solutions:**

- Develop policies for pharmacy staff to document calculations for insulin quantity at order entry and dispensing as an independent double check to enhance accuracy.<sup>9</sup>
- Highlight information related to insulin dosing calculations (e.g. extra units required for priming insulin pens) as a part of pharmacy staff training.

**Table 5.**

Theme 4 – Storage Requirements

The prescription was entered early morning, [the] pharmacist [saw the] patient walking in assuming [the] patient was in to pick up prescription. Patient walked around the store, said she would return, and [the] insulin was put in [the] drawer instead of [the] fridge.

**Potential contributing factors:**

- Environmental distractions
- Confirmation bias

**Potential system-based solution:**

- Develop or reinforce existing policies and procedures with regards to dispensing refrigerated products. Refrigerated products should always be returned to the fridge immediately after filling.

## Conclusions

- Medication incidents involving insulin in pharmacy practice are common and have the potential to cause serious patient harm.
- Findings from this analysis are intended to educate health care professionals on the vulnerabilities in the medication-use process that may contribute to insulin-specific medication incidents and offer recommendations to prevent such events from recurring.
- Creating a culture of patient safety with the support of a non-punitive reporting system needs to be encouraged within all areas of pharmacy practice.

**References**

1. Institute for Safe Medication Practices. ISMP List of High-Alert Medications in Community/Ambulatory Healthcare. 2011. Available from: <http://www.ismp.org/communityRx/tools/ambulatoryhighalert.asp>
2. ISMP Canada. Community Pharmacy Incident Reporting (CPhIR) Database. Available from: <http://www.cphir.ca>
3. Kawano A, Li Q, Ho C. Preventable Medication Errors - Look-alike/Sound-alike Drug Names. *Pharmacy Connection Spring 2014*; 28-33.
4. ISMP Canada. Look-alike/sound-alike drug names: Can we do better in Canada? *ISMP Canada Safety Bulletin 2004*; 4(2):1-2.
5. ISMP Canada. Lowering the risk of medication errors: Independent double checks. *ISMP Canada Safety Bulletin 2005*; 5(1):1-2.
6. ISMP Canada. Patient Report of Insulin Mix-up Shared. *ISMP Canada Safety Bulletin 2007*; 7(6):1-2.
7. ISMP Canada. Risk of mix-ups between Ephedrine and Epinephrine. *ISMP Canada Safety Bulletin 2007*; 7(2):1-2.
8. Cicciario N, Bagnasco L. Look alike/sound alike drugs: A literature review on causes and solutions. *Int J Clin Pharm 2014*; 36(2):233-242.
9. Truong M, Ho C. Methotrexate Medication Incidents in the Community: A Multi-Incident Analysis by ISMP Canada. *Pharmacy Connection Summer 2015*; 32-36.

The authors would like to acknowledge the support from the Ontario Ministry of Health and Long-Term Care for the development of the CPhIR program. CPhIR contributes to the Canadian Medication Incident Reporting and Prevention System (CMIRPS) ([www.ismp-canada.org/cmirms/](http://www.ismp-canada.org/cmirms/)).

**ISMP Canada**  
Institute for Safe Medication Practices Canada  
[www.ismp-canada.org](http://www.ismp-canada.org)

**CMIRPS**  
Canadian Medication Incident Reporting and Prevention System  
[www.ismp-canada.org/cmirms/](http://www.ismp-canada.org/cmirms/)

**CPhIR**  
Community Pharmacy Incident Reporting Program  
[www.cphir.ca](http://www.cphir.ca)

**Disclosures**  
Authors of this poster have the following to disclose concerning possible personal or financial relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation:

- Carolyn Kasprzak – Nothing to disclose
- Certina Ho – Nothing to disclose